Business Description
Atossa Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US04962H5063
Total Employee Number:
14Description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.8 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -9.5 | |||||
3-Year EPS without NRI Growth Rate | -8.6 | |||||
3-Year FCF Growth Rate | -12 | |||||
3-Year Book Growth Rate | -31.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 1.71 | |||||
9-Day RSI | 5.63 | |||||
14-Day RSI | 9.92 | |||||
3-1 Month Momentum % | 1.33 | |||||
6-1 Month Momentum % | -58.91 | |||||
12-1 Month Momentum % | -68.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.92 | |||||
Quick Ratio | 4.92 | |||||
Cash Ratio | 4.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -77.56 | |||||
ROA % | -67.5 | |||||
ROIC % | -971.47 | |||||
3-Year ROIIC % | 214.92 | |||||
ROCE % | -81.6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.5 | |||||
Price-to-Tangible-Book | 0.5 | |||||
EV-to-EBIT | 0.36 | |||||
EV-to-Forward-EBIT | -0.15 | |||||
EV-to-EBITDA | 0.36 | |||||
EV-to-FCF | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 0.52 | |||||
| Price-to-Net-Cash | 0.62 | |||||
Earnings Yield (Greenblatt) % | 277.78 | |||||
FCF Yield % | -190.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atossa Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -83.314 | ||
| Beta | 0.4245 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 67.55 | ||
| 14-Day RSI | 9.92 | ||
| 14-Day ATR (MXN) | 3.227138 | ||
| 20-Day SMA (MXN) | 66.892 | ||
| 12-1 Month Momentum % | -68.31 | ||
| 52-Week Range (MXN) | 31.7 - 322.499999 | ||
| Shares Outstanding (Mil) | 9.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atossa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atossa Therapeutics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 140 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 48 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 100.00 (+0.00%) | ||
| General meeting for 2026 | 2026-05-07 09:00 | 100.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-30 | 110.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 75.00 (+0.00%) | ||
| 0.0666667:1 Stock Split | 2026-02-03 | 159.30 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 227.25 (-2.26%) | ||
| 27th Annual H.C. Wainwright Global Investment Conference | 2025-09-08 15:00 | 223.50 (+2.76%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 215.25 (-1.85%) |
Show
Entries
Atossa Therapeutics Inc Frequently Asked Questions
What is Atossa Therapeutics Inc(MEX:ATOS)'s stock price today?
The current price of MEX:ATOS is MXN31.75. The 52 week high of MEX:ATOS is MXN322.50 and 52 week low is MXN31.70.
When is next earnings date of Atossa Therapeutics Inc(MEX:ATOS)?
The next earnings date of Atossa Therapeutics Inc(MEX:ATOS) is 2026-08-12 Est..
Does Atossa Therapeutics Inc(MEX:ATOS) pay dividends? If so, how much?
Atossa Therapeutics Inc(MEX:ATOS) does not pay dividend.
Press Release
Articles on Atossa Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers